Alcresta

Alcresta Therapeutics is a Massachusetts-based rare disease company dedicated to developing and commercializing novel enzyme-based products that improve nutritional care for enterally fed patients. The company's flagship product, RELiZORB, is the only FDA-cleared enzymatic product studied and indicated for use with enteral feeding, utilizing Alcresta's proprietary iLipase immobilized enzyme technology to address fat malabsorption in patients with conditions such as cystic fibrosis and pancreatic insufficiency. Backed by Linden Capital Partners and HealthQuest Capital, Alcresta has built an extensive intellectual property portfolio while advancing a pipeline of additional enzyme-based solutions for rare gastrointestinal disorders.